A phase II multicenter trial of the multitargeted kinase inhibitor sulfatinib in advanced medullary thyroid cancer (MTC) and radioiodine (RAI)-refractory differentiated thyroid cancer (DTC).

被引：2
|
作者：
Chen, Jiaying
Ji, Qinghai
Cao, Junning
Ji, Dongmei
Bai, Chunmei
Lin, Yansong
Pan, Bin
Sun, Guofang
Li, Jing
Qi, Chuan
Hua, Ye
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Phase Unit, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Canc Ctr, Dept Med Oncol, Shanghai, Peoples R China
[4] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Beijing, Peoples R China
[5] Peking Union Med Coll Hosp, Beijing, Peoples R China
[6] Hutchis MediPharma Ltd, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.6037
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
6037
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Salvage tyrosine kinase inhibitor therapy for differentiated and medullary thyroid cancer.
    Chowdry, R. P.
    Bhimani, C.
    Ramalingam, S. S.
    Khuri, F. R.
    Owonikoko, T. K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [42] Anlotinib in locally advanced or metastatic radioiodine-refractory differentiated thyroid carcinoma: A randomized, double-blind, multicenter phase II trial
    Chi, Y.
    Gao, M.
    Zhang, Y.
    Shi, F.
    Cheng, Y.
    Guo, Z.
    Ge, M.
    Qin, J.
    Zhang, J.
    Li, Z.
    Zhou, X.
    Huang, R.
    Chen, X.
    Liu, H.
    Cheng, R.
    Xu, Z.
    Zheng, X.
    Li, D.
    Tang, P.
    ANNALS OF ONCOLOGY, 2020, 31 : S1215 - S1215
  • [43] Anlotinib in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Carcinoma: A Randomized, Double-Blind, Multicenter Phase II Trial
    Chi, Yihebali
    Zheng, Xiangqian
    Zhang, Yuan
    Shi, Feng
    Cheng, Ying
    Guo, Zhuming
    Ge, Minghua
    Qin, Jianwu
    Zhang, Jiewu
    Li, Zhendong
    Zhou, Xiaohong
    Huang, Rui
    Chen, Xiaohong
    Liu, Hui
    Cheng, Ruochuan
    Xu, Zhengang
    Li, Dapeng
    Tang, Pingzhang
    Gao, Ming
    CLINICAL CANCER RESEARCH, 2023, 29 (20) : 4047 - 4056
  • [44] COST-EFFECTIVENESS OF SORAFENIB FOR TREATMENT OF RADIOACTIVE IODINE (RAI)-REFRACTORY LOCALLY ADVANCED/METASTATIC DIFFERENTIATED THYROID CANCER (DTC) IN TURKEY
    Erdal, E.
    Sayman, H.
    Turkmen, C.
    Aral, F.
    Yildiz, O.
    Okutur, K.
    Parali, E.
    Deger, C.
    Tunalioglu, A.
    Sar, C.
    Asan, S.
    Sumer, F.
    Ozel, O.
    VALUE IN HEALTH, 2015, 18 (03) : A203 - A204
  • [45] COMBINATION CHEMOTHERAPY OF ADVANCED MEDULLARY AND DIFFERENTIATED THYROID-CANCER - PHASE-II STUDY
    SCHERUBL, H
    RAUE, F
    ZIEGLER, R
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1990, 116 (01) : 21 - 23
  • [46] Sunitinib in patients with refractory advanced thyroid cancer: the THYSU phase II trial
    Ravaud, A.
    de la Fouchardiere, C.
    Courbon, F.
    Asselineau, J.
    Klein, M.
    Nicoli-Sire, P.
    Bournaud, C.
    Delord, J.
    Weryha, G.
    Catargi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer (DTC): The phase III DECISION trial
    Bockisch, A.
    Brose, M. S.
    Nutting, C.
    Jarzab, B.
    Elisei, R.
    Siena, S.
    Bastholt, L.
    de la Fouchardiere, C.
    Pacini, F.
    Paschke, R.
    Shong, Y. K.
    Sherman, S. I.
    Smit, J. W.
    Chung, J. W.
    Kappeler, C.
    Molnar, I.
    Schlumberger, M.
    EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2014, 122 (03)
  • [48] Positive results with lenvatinib for the treatment of advanced medullary thyroid cancer in a phase II trial
    Nature Reviews Endocrinology, 2015, 11 (11) : 632 - 632
  • [49] Donafenib in Progressive Locally Advanced or Metastatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Results of a Randomized, Multicenter Phase II Trial
    Lin, Yan-Song
    Yang, Hui
    Ding, Yong
    Cheng, Yi-Zhuang
    Shi, Feng
    Tan, Jian
    Deng, Zhi-Yong
    Chen, Zhen-Dong
    Wang, Rong-Fu
    Ji, Qing-Hai
    Huang, Rui
    Li, Lin-Fa
    THYROID, 2021, 31 (04) : 607 - 615
  • [50] Phase II trial of sorafenib in advanced thyroid cancer
    Gupta-Abramson, Vandana
    Troxel, Andrea B.
    Nellore, Anoma
    Puttaswamy, Kanchan
    Redlinger, Maryann
    Ransone, Kathy
    Mandel, Susan J.
    Flaherty, Keith T.
    Loevner, Laurie A.
    O'Dwyer, Peter J.
    Brose, Marcia S.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (29) : 4714 - 4719
12345